Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer

Foluso O. Ademuyiwa, Kathy D. Miller

Research output: Contribution to journalArticle

11 Scopus citations


Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent results of large randomized trials show clinically significant improvements in outcomes with the use of bevacizumab in patients with metastatic breast cancer, leading to approval by European and US regulatory agencies. Several other antiangiogenic strategies are in various stages of development. This review discusses the results of recent clinical trials and novel mechanisms of inhibiting angiogenesis, resistance mechanisms, and toxicities; and raises key challenges that face optimal use and development of antiangiogenic agents in breast cancer.

Original languageEnglish (US)
Pages (from-to)S151-S156
JournalClinical breast cancer
Issue numberSUPPL. 4
StatePublished - Jan 1 2008
Externally publishedYes


  • Bevacizumab
  • Pazopanib
  • Tamoxifen
  • Tyrosine kinase inhibitors
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this